These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18790059)

  • 1. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.
    Westerlund M; Ran C; Borgkvist A; Sterky FH; Lindqvist E; Lundströmer K; Pernold K; Brené S; Kallunki P; Fisone G; Olson L; Galter D
    Mol Cell Neurosci; 2008 Dec; 39(4):586-91. PubMed ID: 18790059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
    Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
    Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 expression linked to dopamine-innervated areas.
    Galter D; Westerlund M; Carmine A; Lindqvist E; Sydow O; Olson L
    Ann Neurol; 2006 Apr; 59(4):714-9. PubMed ID: 16532471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
    Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
    Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
    Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
    eNeuro; 2019; 6(6):. PubMed ID: 31685675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
    Oeckl P; Hengerer B; Ferger B
    Exp Neurol; 2014 Jul; 257():1-9. PubMed ID: 24747358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
    Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
    Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
    Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
    Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
    Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
    Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM
    J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.
    Beccano-Kelly DA; Volta M; Munsie LN; Paschall SA; Tatarnikov I; Co K; Chou P; Cao LP; Bergeron S; Mitchell E; Han H; Melrose HL; Tapia L; Raymond LA; Farrer MJ; Milnerwood AJ
    Hum Mol Genet; 2015 Mar; 24(5):1336-49. PubMed ID: 25343991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein.
    Brzozowski CF; Hijaz BA; Singh V; Gcwensa NZ; Kelly K; Boyden ES; West AB; Sarkar D; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2021 Nov; 9(1):180. PubMed ID: 34749824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
    Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
    Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.